Supernus Pharmaceuticals (SUPN) Income towards Parent Company (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Income towards Parent Company data on file, last reported at -$4.1 million in Q4 2025.

• Income towards Parent Company for Q4 2025 came in at -$4.1 million, down 126.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.8 million (down 143.19% YoY), and the FY2025 annual result was -$38.6 million, down 152.19% from the prior year.
• Income towards Parent Company grew to -$4.1 million in Q4 2025 per SUPN's latest filing, from -$45.1 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $38.5 million in Q3 2024 and troughed at -$45.1 million in Q3 2025.
• A 5-year average of $7.5 million and a median of $6.8 million in 2021 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 2494.95% in 2024, then sank 9637.9% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at $2.4 million in 2021, then surged by 944.55% to $25.5 million in 2022, then plunged by 95.54% to $1.1 million in 2023, then surged by 1248.11% to $15.3 million in 2024, then tumbled by 126.97% to -$4.1 million in 2025.
• Business Quant data shows SUPN's Income towards Parent Company at -$4.1 million in Q4 2025, -$45.1 million in Q3 2025, and $22.5 million in Q2 2025.